INTRODUCTION

Lung cancer is the leading cause of cancer death in the United
States with an estimated 160 340 deaths annually. 1 Non-small cell lung cancer (NSCLC), which accounts for B85% of lung cancer diagnoses, exhibits a 5-year survival rate of only 16%, 1 underscoring the importance of understanding both tumor promoting and tumor suppressive signaling pathways that drive NSCLC in order to identify potential therapeutic targets for better treatment strategies.
Protein kinase C (PKC) represents a family of ten structurallyrelated lipid-dependent serine/threonine kinases involved in cellular proliferation, differentiation and survival. The identification of PKC enzymes as intracellular receptors for the tumor promoting phorbol esters 2, 3 provided a suggestive causal link between PKCs and cellular transformation. However, the relationship between specific PKC isozymes and cancer is complex. 4 Individual PKC isozymes exhibit cell type-specific expression patterns and complex signaling responses through different subcellular localization, substrate selection, and cofactor requirements. As a result, closely related PKC isozymes often have distinct, sometimes opposing roles in cancer. 4 For example, PKC epsilon (PKCe) promotes cell proliferation and survival, 5 and overexpression of PKCe increases anchorage-independent cell growth and tumorigenicity of NIH 3T3 cells. 6 In contrast, the closely related isozyme, PKC delta (PKCd), promotes apoptosis and inhibits NIH 3T3 cell growth. 6 The opposing roles of PKCe and PKCd are also observed in vivo. Transgenic overexpression of PKCe in the epidermis promotes carcinogen-induced tumor formation, whereas overexpression of PKCd is protective. 7, 8 A similar dichotomy of function is seen in the two atypical PKC isozymes PKCi and PKCz. 9, 10 We have shown that atypical PKCi is an oncogene in NSCLC. 11 PKCi is overexpressed in primary human NSCLC tumors as a result of recurrent tumor-specific gene amplification, and PKCi is required for anchorage-independent growth and tumorigenesis of human NSCLC cells in vivo. 11, 12 Additionally, PKCi is required for Kras-mediated lung tumor initiation in the LSL-Kras model. 13 PKCi also has a tumor promotive role in colon, 14 ovarian, 15, 16 leukemia, 17, 18 pancreatic 19, 20 and alveolar rhabdomyosarcoma 21 cancers. Given the direct involvement of PKCi in tumorigenesis, we developed a novel therapeutic that selectively target oncogenic PKCi signaling, 9, 22, 23 which is currently being evaluated in the clinic. In contrast, the highly related atypical PKCz isozyme exhibits tumor suppressor activity in multiple tissues, including the ovary 24 and lungs.
PKC alpha (PKCa) is particularly interesting as it exhibits both tumor promoting and tumor suppressive activity depending upon cellular context. In hepatocellular carcinoma cells, PKCa knockdown reduces cell growth, migration and invasion, indicating a tumor promotive role. 26 In contrast, activation of PKCa in LNCaP prostate cancer cells induces increased apoptosis suggesting a tumor suppressive activity. 27 Likewise, genetic deletion of the PKCa gene Prkca in APC min/ þ mice increased tumor size and reduced survival, supporting a tumor suppressive role in the colon. 28 The role of PKCa in lung cancer is uncertain. On the one hand, selective activation of PKCa in NSCLC cells during S phase results in cellular senescence through G 2 /M cell cycle arrest, 29 whereas inhibition of PKCa during G 1 phase does not affect cell growth. 30 Therefore, the question still remains whether PKCa is tumor promoting or tumor suppressive in the lung, and no studies have assessed the role of PKCa in lung tumorigenesis in vivo. To address this question, we assess the role of PKCa in three independent transgenic mouse models of Kras-driven lung tumorigenesis. We observed a significant increase in tumor number, burden and grade as a result of PKCa loss. This effect is reflected in enhanced expansion of bronchio-alveolar stem cells (BASCs), tumor-initiating cells in these models, in the absence of PKCa. PKCa-mediated tumor suppression involves activation of a p38 MAPK-TGFb signaling axis that induces cellular growth arrest in vitro, and enforces oncogene-induced senescence (OIS) in vivo. 
RESULTS
PKCa expression is frequent decreased in human lung tumors
We first analyzed PKCa expression in human NSCLC gene expression data sets. The NextBio database revealed that PKCa is significantly downregulated in adenocarcinoma, squamous cell carcinoma and large cell carcinoma, the three major NSCLC subtypes (Figure 1a) . Interestingly, PKCa loss increased with tumor stage suggesting a role in tumor progression. Immunohistochemistry confirmed loss of PKCa in primary lung adenocarcinoma cells compared with the surrounding stroma (Figure 1b) . Loss of PKCa was also observed in lung adenomas from LSL-Kras mice (Figure 1c) . In LSL-Kras tumors, PKCa loss was greater in some areas of the tumor than others. These results are consistent with progressive PKCa loss with advanced tumor stage as LSL-Kras lung tumors are early stage adenomas. Thus, PKCa loss occurs in both primary human NSCLC tumors and LSL-Kras adenomas.
PKCa inhibits Kras-dependent tumor initiation We next assessed the role of PKCa loss in Kras-mediated lung tumorigenesis using mice harboring constitutive deletion of Prkca (Prkca À / À mice). 59 Functional loss of PKCa was confirmed by quantitative PCR (Figure 2a À / À mice. Oncogenic Kras expression and lung tumorigenesis was initiated by intratracheal instillation of recombinant adenovirus expressing Cre recombinase as described previously. 31 LSL-Kras/Prkca À / À mice exhibited a significant decrease in median survival (196 days) compared with LSL-Kras mice (251 days; Po0.0001) (Figure 2b ). Decreased survival correlated with a significant increase in tumor number, size and burden in LSL-Kras/ Prkca À / À mice ( Figure 2c ). To assess the generality of these results, we assessed tumor formation in Ntg or Prkca À / À mice after exposure to the lung carcinogen urethane (Figure 2d ), and in Kras LA2/ þ mice (Figure 2e ), in which oncogenic Kras is spontaneously activated by homologous recombination. 32 In both models, PKCa-deficiency resulted in a significant increase in tumor number and burden. Lung tumorigenesis was strictly dependent upon carcinogen exposure and/or oncogenic Kras activation as no tumors were observed in Ntg or Prkca À / À mice in the absence of tumor initiators (data not shown).
Loss of PKCa induces tumor progression and bypass of OIS Pathological examination revealed a significant increase in tumor progression in LSL-Kras/Prkca À / À tumors compared with LSL-Kras tumors. LSL-Kras/Prkca À / À mice tumors exhibited nuclear crowding, increased mitotic figures, nuclear swelling and highly variable nuclear morphologies (Figure 3a , right panel), all characteristics of progression from adenoma to carcinoma in this model. 33 In contrast, most LSL-Kras tumors did not exhibit these characteristics, and were classified as adenomas (Figure 3a , left panel). Quantitative analysis revealed progression to carcinoma in all LSL-Kras/Prkca À / À mice (14/14) but in only 20% (3/15) of LSLKras mice (P ¼ 0.00001; Fisher's exact test). In LSL-Kras mice, progression to carcinoma is suppressed due to OIS in the presence of oncogenic Kras. 34 OIS is characterized by widespread expression of the tumor suppressive cell cycle inhibitor p16
Ink4A . 35 As expected, LSL-Kras tumors exhibited widespread OIS as evidenced by positive staining for p16 and relatively low Ki67 staining (Figure 3c ). Interestingly, LSL-Kras tumors exhibited regions that stained positive for both PKCa and p16, while other areas expressed low PKCa and p16 staining. In contrast, LSL-Kras/ Prkca À / À tumors exhibited uniformly low p16 expression and increased Ki67 staining consistent with OIS bypass, increased tumor growth and tumor progression (Figure 3c ).
Loss of PKCa stimulates Kras-mediated BASC expansion As PKCa inhibits initiation of Kras-driven lung tumors, we hypothesized that PKCa may inhibit expansion of BASCs, putative tumor-initiating cells in this model. 36 Therefore, we quantitated BASCs within the terminal bronchioles (TB) of LSL-Kras and LSL-Kras/Prkca À / À mice in vivo as described previously. 13, 36 As expected, most TB from Ntg mice contained either no BASCs or a single BASC (Figure 4a ). Interestingly, Prkca À / À mice exhibited no change in BASC number, indicating that PKCa is not a major factor regulating basal BASC number. In contrast, both LSL-Kras and LSLKras/Prkca À / À mice exhibited a statistically significant increase in BASCs (more TB exhibiting two or more BASCs) when compared with Ntg mice. Analysis of BASC multiplicity demonstrated that LSL-Kras/Prkca À / À mice exhibit a significantly larger expansion of BASCs than LSL-Kras mice (more bronchioles of higher BASC multiplicity) (Figure 4b ). To assess whether this difference is due to a direct effect of PKCa loss on BASCs, we assessed the growth of isolated BASC cultures ex vivo. BASCs isolated and purified from Ntg, Prkca À / À , LSL-Kras and LSL-Kras/Prkca À / À mice as described previously, 36 were treated with adenoviral Cre to induce oncogenic Kras, and plated in three dimensional Matrigel culture as described previously. 13 Quantitative analysis of BASC colonies grown ex vivo for 7 days demonstrate that loss of PKCa had little effect on BASC colony size in the absence of Kras, whereas oncogenic Kras expression resulted in a significant increase in BASC colony size, which was further enhanced by deletion of PKCa ( Figure 4c ). A similar increase in colony size was observed in BASCs from LSL-Kras mice treated with the selective PKCa/b inhibitor Gö 6976 (Figure 4d ) indicating that the effect of PKCa on the transformed growth of BASCs is dependent upon acute PKCa kinase activity. Thus, PKCa directly regulates BASC growth in the presence of oncogenic Kras.
p38 MAPK is a downstream effector of PKCa in Kras-induced tumorigenesis p38 MAPK has a key role in oncogenic Ras-induced senescence and p16
Ink4A induction. 37, 38 p38 MAPK is phosphorylated and activated downstream of PKCa, and functions in the tumor promoting and suppressive effects of PKCa. 26, 27 Furthermore, the enhanced lung tumorigenesis observed in LSL-Kras/Prkca À / À mice is similar to that seen in p38 MAPK-deficient mice on the LSLKras background. 39 Therefore, we assessed whether p38 MAPK activation is modulated by PKCa in BASCs and LSL-Kras-induced lung tumors. Immunoblot analysis revealed decreased phosphop38 MAPK in BASCs from LSL-Kras/Prkca À / À mice compared with LSL-Kras mice (Figure 5a ). The effect of PKCa loss was selective for phospho-p38 MAPK as we observed little or no change in either total p38 MAPK, or total or phospho-Erk1/2 ( Figure 5a ). Addition of the selective p38 MAPK inhibitor SB203580 induced enhanced growth of BASCs from LSL-Kras mice, resulting in colonies comparable to those from LSL-Kras/Prkca À / À mice while having no effect on BASCs from Ntg or LSL-Kras/Prkca À / À mice (Figure 5b) . Furthermore, LSL-Kras/Prkca À / À tumors exhibited reduced phospho-p38 MAPK staining compared with LSL-Kras tumors, indicating that p38 MAPK activity is regulated by PKCa in vivo (Figure 5c ). Thus, p38 MAPK is selectively activated downstream of PKCa during LSL-Kras-induced lung tumorigenesis, and is likely involved in PKCa-mediated inhibition of tumor growth and progression.
TGFb1 mediates the effects of PKCa loss on BASC expansion The TGFb pathway is normally tumor suppressive, but in the presence of oncogenic Ras can become pro-oncogenic. 40 Interestingly, TGFb1 expression is elevated in p38 MAPKdeficient mice expressing oncogenic Kras, 39 suggesting that a PKCa-p38 MAPK signaling axis may regulate lung tumorigenesis through TGFb signaling. Consistent with this possibility, quantitative PCR analysis demonstrated a small but significant increase in TGFb1 mRNA expression in LSL-Kras/Prkca À / À BASCs compared with LSL-Kras BASCs (Figure 6a ) and addition of exogenous TGFb1 led to a significant increase in growth of LSLKras BASCs, while having no significant effect on Ntg or LSL-Kras/ Prkca À / À BASCs (Figure 6b ). In addition, treatment with the selective TGFbR1 inhibitor SB431542 blocked growth of LSL-Kras/ Prkca À / À BASCs while having no significant effect on growth of Ntg or LSL-Kras BASCs (Figure 6c ). Taken together, these data demonstrate that TGFb signaling can mediate PKCa-regulated transformed growth, and indicate that PKCa inhibits lung tumor cell growth, at least in part, by suppressing TGFb signaling.
PKCa regulates expression of the inhibitors of DNA binding (Id) protein family Our results in LSL-Kras/Prkca À / À mice is consistent with the tumor suppressive effect of PKCa in the colon. 41, 42 In colon cancer, PKCa inhibits cell cycle by negatively regulating expression of the Id family of proteins, Id1-4. 41, 42 Indeed, LSL-Kras/Prkca À / À BASCs express significantly more Id1-3 but not Id4 compared with LSL-Kras BASCs (Figure 7a ). PKCa-dependent Id gene expression requires p38 MAPK activity as Id1-3 mRNA is increased in LSL-Kras BASCs treated with the p38 MAPK inhibitor SB203580 (Figure 7b) . Furthermore, Id1-3 expression was significantly decreased in LSL-Kras/Prkca À / À BASCs treated with the TGFbR1 inhibitor SB431542 (Figure 7c) . Thus, PKCa suppresses expression of Id family members through a p38 MAPK-TGFb1 signaling pathway, suggesting that Id proteins may be central players in the PKCa-mediated regulation of lung tumor growth.
Deletion of PKCa induces Wilm's Tumor 1 (WT1) during Kras-induced lung tumorigenesis Our data demonstrate that loss of PKCa leads to bypass of OIS and tumor progression (Figure 3 ). This phenotype is strikingly similar to that seen in transgenic mice overexpressing the WT1 gene on the LSL-Kras background. 43 LSL-Kras/Tg WT1 mice exhibit enhanced tumorigenesis and tumor progression as a result of OIS bypass. 43 WT1 mRNA was elevated in LSL-Kras/Prkca À / À BASCs compared with LSL-Kras BASCs (Figure 8b) . Additionally, immunohistochemistry revealed that WT1 is elevated in LSL-Kras/Prkca À / À compared with LSL-Kras tumors (Figure 8b) , and treatment of LSL-Kras BASCs with the p38 MAPK inhibitor SB203580 led to induction of WT1 (Figure 8c) . Finally, WT1 expression in LSL-Kras/ Prkca À / À BASCs was reduced after treatment with the TGFbR inhibitor SB431542 (Figure 8d ). These data are consistent with a role for WT1 in facilitating OIS bypass downstream of PKCa loss in lung tumorigenesis. 44 ). There are conflicting reports regarding the role of PKCs in general, and PKCa specifically, in tumorigenesis and progression. These disparate results may be due to differences in cell-and tumor-type function, results obtained in cell lines in vitro versus in transgenic animal models in vivo, and the specificity of reagents used to identify PKCa function. Here we demonstrate that PKCa is a tumor suppressor in vivo using three models of Krasmediated lung cancer. Genetic loss of PKCa in murine lung results in enhanced tumor growth and progression to carcinoma upon activation of oncogenic Kras. These results are consistent with the progressive loss of PKCa in primary human NSCLC tumors with advancing tumor stage. As PKCs are capable of phosphorylating Kras, leading to its association with mitochondrial BCL-XL and induction of cellular apoptosis, 45 it will be of interest to assess whether such a mechanism also contributes to the tumor suppressor effects observed here. While our studies focused on Kras-mediated lung adenocarcinoma, human gene expression data indicate that PKCa is frequently lost in other major forms of NSCLC, including lung squamous cell carcinoma, which does not harbor frequent Kras mutations. Likewise, PKCa has a tumor suppressive role in APC min intestinal tumorigenesis, 28 indicating that the tumor suppressive role of PKCa extends beyond Krasdriven tumors. Whether the signaling mechanisms involved in PKCa-mediated tumor suppression differ depending upon oncogenic drivers is an important area for future investigation.
DISCUSSION
In addition to a role in tumor progression, our animal studies reveal an additional, unexpected role for PKCa in tumor initiation.
LSL-Kras/Prkca
À / À mice exhibit enhanced expansion of tumorinitiating BASCs, an effect that appears to be due, at least in part, to a direct effect of PKCa loss on the growth of Kras-transformed BASCs. As Prkca À / À mice harbor constitutive, organism-wide loss of PKCa, we cannot exclude an additional contribution of PKCa expressed in tumor-associated stroma and immune cells in tumor suppression in vivo. Such an analysis will require more complex animal models, in which PKCa expression can be conditionally controlled in a tissue-and time-specific manner.
Mechanistically, our data indicate that PKCa has a key role in enforcement of OIS in vivo. LSL-Kras/Prkca À / À tumors exhibit reduced p16
Ink4A expression, an increase in Ki67 staining and progression to adenocarcinoma, consistent with OIS bypass. Interestingly, we observed regional coexpression of PKCa and p16
Ink4A in LSL-Kras tumors, suggesting that PKCa loss during Krasmediated tumorigenesis may represent an intrinsic mechanism by which these tumors overcome OIS. Our findings with PKCa loss bear a striking resemblance to those observed with genetic loss of p38 MAPK, 39 suggesting a functional link between these genes. Indeed, our mechanistic studies reveal that p38 MAPK is a key downstream mediator of PKCa that regulates tumor initiation, at least in part, through control of Kras-mediated transformation of tumor-initiating BASCs. Our data are consistent with published reports demonstrating a key role of p38 MAPK in OIS 37, 38 and provide the first demonstration that a PKCa-p38 MAPK signaling axis has a role in OIS in Kras-mediated lung tumorigenesis in vivo. These results are also consistent with the finding that PKCa can regulate senescence in lung cancer cell lines in vitro.
29
Our results provide compelling evidence for a PKCa-p38 MAPKTGFb signaling axis that drives the tumor suppressive effects of PKCa. Interestingly, genetic loss of PKCa in Kras-transformed BASCs resulted in a small but highly reproducible increase in TGFb1 expression. This effect, though modest, is functionally relevant as exogenous TGFb1 can mimic PKCa loss, and inhibition of TGFb signaling reverses the effect of PKCa loss on BASC growth. Therefore, suppression of TGFb signaling is a key mechanism by which PKCa inhibits lung cancer initiation and progression. Given the modest change in TGFb1 mRNA abundance, PKCa likely also regulates other aspects of TGFb signaling in the lung. In this regard, PKCa facilitates internalization of TGFbR from the cell surface in podocytes, 46 and PKCa induces expression of both TGFb1 and TGFbR1 in vascular smooth muscle cells. 47 Our data suggest involvement of TGFbR1 in TGFb signaling activation mediated by PKCa loss, as treatment with the TGFbR1/ALK5 selective inhibitor SB431542 inhibits the enhanced growth of LSL-Kras/Prkca À / À BASCs. TGFb, like PKCa, can be either tumor promoting or tumor suppressive depending on cellular context. The Id family of genes is negatively-regulated by PKCa in colon cancer 41, 42 where PKCa loss results in increased expression of Id1-4 which in turn regulate cyclin D1 and cell cycle progression. 41 Consistent with these findings, we show that PKCa negatively regulates Id1-3 in BASCs. The effect of PKCa on Id expression requires the novel PKCa-p38 MAPK-TGFb1 signaling axis characterized in this report. We hypothesize that PKCa functions as a tumor suppressor in lung, at least in part through inhibition of expression of Id genes, which in turn mediate PKCa-induced inhibition of BASC and lung tumor cell growth. The effect of PKCa loss on Kras-induced lung tumorigenesis is reminiscent of the phenotype observed in WT1-overexpressing mice in the presence of oncogenic Kras.
43 While WT1-overexpressing mice exhibit enhanced Kras-driven tumorigenesis, mice lacking WT1 exhibit enhanced OIS. 43 PKCa loss leads to increased WT1 expression through a p38 MAPKTGFb-dependent pathway, consistent with the finding that WT1 expression is regulated by TGFb signaling. 48 Our data suggest that WT1 is a relevant downstream target involved in mediating OIS bypass in LSL-Kras/Prkca À / À mice. Analysis of gene expression data sets revealed a significant inverse relationship between PKCa and both WT1 and Id1 expression in primary human NSCLC tumors (Po0.02 for Id1; Po0.0002 for WT1), indicating the relevance of tumor PKCa loss in induction of WT1 and Id1 expression in primary human NSCLC.
Finally, our results have important implications for therapeutic intervention strategies targeting PKCa. The first isozyme-selective PKC inhibitor to enter clinical use was a 20-base antisense oligonucleotide targeting PKCa (LY900003/Aprinocarsen). Aprinocarsen inhibited PKCa expression and exhibited anti-tumor activity in nude mouse xenograft models. 49, 50 However, no clinical benefit was observed in phase II clinical trials of Aprinocarsen as a single agent in ovarian cancer 51 or high-grade glioma. 52 Likewise, a large phase III clinical trial of Aprinocarsen in combination with gemcitabine and cisplatin in advanced NSCLC failed to demonstrate any survival benefit or difference in response. 53 Therefore, despite encouraging preclinical data, PKCa has not been a successful target for cancer treatment. Our current study, and others cited herein, indicate that PKCa suppresses rather promotes tumorigenesis in the colon and the lung, calling into question the rationale for PKCa inhibitors in cancer therapy, at least in these tumor types.
MATERIALS AND METHODS
Analysis of publicly available gene expression data sets
PKCa, WT1 and Id1 expression was assessed in publicly available gene expression data sets of human NSCLC tumors. All statistical analyses were completed using the 'R Statistical Computing Language'. 54 Microarray data sets for human NSCLC samples were normalized using the preprocess Core function of the R program package, and linear regression modeling was conducted to determine differentially expressed genes between groups. 55 Correction for multiple testing was conducted and a false discovery rate of 0.05 was used as a cutoff. Human microarray data sets (accession id: GSE18842, 56 GSE19188, 57 GSE1987, 58 GSE3398, GSE27556 and GSE2109) are available for download from the Gene Expression Omnibus (http:// www.ncbi.nlm.nih.gov/geo).
Kras models of lung tumorigenesis
Three independent mouse models of Kras-mediated lung tumorigenesis were used to analyze the role of PKCa in lung cancer development and progression. In the first model, LSL-Kras mice (C57BL/6J) 31 were mated with Prkca À / À mice (C57BL/6J:129/SV) 59 to generate bitransgenic LSL-Kras/ Prkca À / À mice. Tumorigenesis was initiated by installation of adenoviral Cre recombinase (final concentration 1.5 Â 10 8 PFU/ml) intratracheally in two 50 ml doses into 6 to 8-week-old mice as described previously 60 number and burden. In the third model, 6-week-old Ntg and Prkca À / À mice were injected intraperitoneally once a week for 6 weeks with 1 mg/kg urethane in 0.9% NaCl as previously described. 62 The mice were killed 6 weeks after cessation of urethane exposure and the lungs harvested and assessed for tumor number and burden. All experiments used littermates from transgenic crosses as controls to control for possible strain differences. All animal experiments were approved by the Mayo Clinic Institutional Animal Care and Use Committee.
Immunohistochemistry and Immunofluorescence
LSL-Kras and LSL-Kras/Prkca
À / À mice were sacrificed 12 weeks after adenoviral Cre instillation and lungs were formalin-fixed, embedded in paraffin, serially sectioned and stained with H&E for histology and immunohistochemical analysis as described previously. 11, 13, 63 H&E-stained sections were imaged using Aperio ScanScope XT (Vista, CA, USA) and analyzed using Aperio ImageScope (v11.1.2.752) to determine tumor number, area, burden and pathological assessment of tumor staging. Sections were stained for PKCa (Abcam, Cambridge, MA, USA; no. ab32376), p16 (Santa Cruz, Dallas, TX, USA; sc-1207), Ki67 (Dako, Carpinteria, CA, USA), phospho-p38 MAPK (Cell Signaling, Danvers, MA, USA; no. 9211) and WT1 (Santa Cruz sc-192) using antibodies diluted in PBS/Tween and visualized using Envision Plus Dual Labeled Polymer Kit following the manufacturer's instructions (DAKO).
BASCs were identified and quantitated in formalin-fixed mouse lung sections as described previously. 13, 64 The number of SPC-, CCSP-positive BASCs per TB was determined using Image-Pro Plus 6.3 and analyzed for statistical significance as described previously. 13 The number of mice and TB analyzed in Figures 4b and c 
BASC isolation and ex vivo culture
BASCs were isolated as previously described. 13 Isolated BASCs were resuspended in BEGM (Lonza, Basel, Switzerland) media without hydrocortisone containing keratinocyte growth factor (10 ng/ml; PeproTech, Rocky Hill, NJ, USA) and 5% charcoal stripped fetal bovine serum and plated onto Matrigel (BD Biosciences, San Jose, CA, USA)-coated tissue culture plates. Cells were incubated with adenoviral Cre (75 PFU/ cell). p38 MAPK inhibitor SB203580 (1 mM), PKC inhibitor Go6976 (10 nM), recombinant TGFb1 (1 ng/ml), or TGFbR inhibitor SB431542 (as indicated in the figure legends) were added to the media 24 h after plating, and the media was changed every 2 days. Bright-field images were captured using an Olympus (Center Valley, PA, USA) IX71 microscope and colony size was determined after 7 days using Image-Pro Plus 6.3 software (Media Cybernetics, Rockville, MD, USA).
Quantitative PCR analysis
BASCs were released from Matrigel using BD cell recovery solution following the manufacturer's instructions (BD Bioscience). Total RNA was isolated using RNAqueous (Ambion, Grand Island, NY, USA) and RNA quantity and quality assessed using a NanoDrop ND-1000 spectrophotometer. quantitative PCR was performed using reagents purchased from Applied Biosystems (Foster City, CA, USA) to detect mouse PKCa, TGFb1, Id1-4 and WT1 using an Applied Biosystems (Grand Island, NY, USA) ViiA7 PCR machine. Data were analyzed using ViiA 7 software and mRNA expression was normalized to 18S RNA. 
